Keywords: strong, preclinical, data, aeterna, cancer, drug, drugmaker

Strong preclinical data for AEterna's cancer drug

Article | 05 February 2007

Print This

US drugmaker AEterna Zentaris presented strong in vivo data on ZEN-012, its novel, oral anticancer compound, at the 7th Joint ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in